Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY4R | P50391 | 15/20 | 0.44 |
| ▸ | NPY1R | P25929 | 9/20 | 0.44 |
| ▸ | NPY5R | Q15761 | 8/20 | 0.44 |
| ▸ | NPY2R | P49146 | 5/20 | 0.44 |
| ▸ | SIRT5 | Q9NXA8 | 2/20 | 0.40 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.36 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27113592 | 0.93 | NPY4R (0.47) | NPY4RNPY1RNPY5RNPY2RSIRT5 | |
| SCHEMBL14012343 | 0.92 | NPY4R (0.41) | NPY4RNPY1RNPY5RNPY2RSIRT5 | |
| SCHEMBL14845337 | 0.90 | NPY4R (0.38) | NPY4RNPY1RNPY5RNPY2RSIRT5 | |
| SCHEMBL24765373 | 0.89 | NPY4R (0.42) | NPY4RNPY1RNPY5RNPY2RSIRT5 | |
| SCHEMBL27113590 | 0.86 | NPY4R (0.41) | NPY4RNPY1RNPY5RNPY2RSIRT5 | |
| SCHEMBL19069865 | 0.83 | NPY4R (0.47) | NPY4RNPY1RNPY5RNPY2RSIRT5 | |
| SCHEMBL27113031 | 0.83 | ENPEP (0.41) | NPY4RNPY1RNPY5RNPY2R | |
| SCHEMBL24157931 | 0.82 | NPY4R (0.40) | NPY4RNPY1RNPY5RNPY2RSIRT5 | |
| SCHEMBL16439029 | 0.82 | NPY4R (0.47) | NPY4RNPY1RNPY5RNPY2RSIRT5 | |
| SCHEMBL18264748 | 0.82 | NPY4R (0.47) | NPY4RNPY1RNPY5RNPY2RSIRT5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240066135-A1 | DRUG CONJUGATES AND USES THEREOF | SUPERTRANS MEDICAL LTD (IL) | 2024-02-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240066135-A1 | DRUG CONJUGATES AND USES THEREOF | SLC7A1, ABCB11, SLC1A5 | NPY4R 3178/4885NPY1R 3757/4885NPY5R 2907/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.